The role and mechanism of butyrate in the prevention and treatment of diabetic kidney disease

Xi Cheng¹,²,³†, Tingting Zhou¹,²,³*, Yanqiu He¹,²,³†, Yumei Xie², Yong Xu¹,²,³* and Wei Huang¹,²,³*

¹Department of Endocrinology and Metabolism, Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Affiliated Hospital of Southwest Medical University, Luzhou, China, ²Sichuan Clinical Research Center for Nephropathy, Luzhou, China, ³Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, China

Diabetic kidney disease (DKD) remains the leading cause of the end-stage renal disease and is a major burden on the healthcare system. The current understanding of the mechanisms responsible for the progression of DKD recognizes the involvement of oxidative stress, low-grade inflammation, and fibrosis. Several circulating metabolites that are the end products of the fermentation process, released by the gut microbiota, are known to be associated with systemic immune-inflammatory responses and kidney injury. This phenomenon has been recognized as the “gut–kidney axis.” Butyrate is produced predominantly by gut microbiota fermentation of dietary fiber and undigested carbohydrates. In addition to its important role as a fuel for colonic epithelial cells, butyrate has been demonstrated to ameliorate obesity, diabetes, and kidney diseases via G-protein coupled receptors (GPCRs). It also acts as an epigenetic regulator by inhibiting histone deacetylase (HDAC), up-regulation of miRNAs, or induction of the histone butyrylation and autophagy processes. This review aims to outline the existing literature on the treatment of DKD by butyrate in animal models and cell culture experiments, and to explore the protective effects of butyrate on DKD and the underlying molecular mechanism.

KEYWORDS
butyrate, diabetic kidney disease, immune, inflammation, epigenetics

Introduction

Diabetic kidney disease (DKD) is a serious microvascular complication of diabetes mellitus and is also the leading cause of the end-stage renal disease (Marshall, 2016). Based on data from International Diabetes Federation, over 40% of patients with diabetes will develop DKD. This causes an increase in health care costs, cardiovascular events risks, and mortality. The etiology and pathogenesis of DKD are complex and have not been completely understood. It mainly includes hemodynamic changes, oxidative stress, insulin resistance, and the release of pro-inflammatory cytokines. All these events lead to glomerulosclerosis, tubular atrophy, fibrosis, and irreversible renal injury (Kawanami et al., 2016). Thus, the
Overview of butyrate and butyrate-mediated responses

Origin, production, transport, and distribution of butyrate

As shown in Figure 1, butyrate is generally thought to be generated by bacterial fermentation of dietary fiber that enters the colon after digestion in the upper gastrointestinal tract (Bergman, 1990; Simpson and Campbell, 2015). The bacteria involved in butyrate production are widespread, the two most important clusters being Faecalibacterium prausnitzii in the Clostridium leptum cluster and Eubacterium rectale/Roseburia spp. in the Clostridium cocoides cluster of Firmicutes (Mokhtari et al., 2017). In a normal human feces sample, each typically accounts for 5–10% of the total microbial load that may be detected (Haenen et al., 2013). Some of these butyrate-producing bacteria are also scattered in clusters IX, XV, XVI, and XVII (Haenen et al., 2013).

Butyrate is produced via two metabolic pathways: firstly, butyryl-coenzyme A (CoA) is phosphorylated to form butyryl-phosphate, which is then converted to butyrate via butyrate kinase (Louis and Flint, 2017). Secondly, the CoA moiety of butyryl-CoA is transferred to butyrate and acetyl-CoA via butyryl-CoA: acetyl-CoA-transferase (Trachsel et al., 2016). The butyrate’s absorption mechanisms through the apical membrane of colon cells include monocarboxylate transporters and sodium-coupled monocarboxylate transporters (Kumar et al., 2015; Counillon et al., 2016). These transporters are diffusely expressed from the central nervous system to peripheral tissues, including liver, fat, heart, and kidney tissues.

Butyrate ameliorates metabolic disorder and kidney injury

Studies have demonstrated a protective effect of butyrate by improving body weight, blood glucose, lipid distribution, and insulin sensitivity in animal models of obesity and diabetes, which can be postulated as new therapeutic strategy to counteract obesity and insulin resistance (Gao et al., 2009; Khan and Jena, 2016; Mollica et al., 2017; Hu et al., 2018). The butyrate-mediated secretion of glucagon-like peptide-1 may mediate the reduction of insulin sensitivity and diabetes (Bridgeman et al., 2021). Glucagon-like peptide-1 has been shown to reduce hepatic gluconeogenesis and stimulate insulin secretion (Jin and Weng, 2016). Increased levels of butyrate-induced glucose transporter 4 in adipose tissues is also a crucial factor hypothesized to be responsible for the improvement in levels of glucose metabolites (Si et al., 2018). The current studies suggest that butyrate improves acute-chronic kidney injury that has been induced by ischemia–reperfusion (Zheng et al., 2019; Sun et al., 2022), contrast agent (Machado et al., 2012); gentamicin (Sun et al., 2013); doxorubicin (Felizardo et al., 2019), hypertension (Wu et al., 2021), and lipopolysaccharide (LPS; Huang et al., 2017; Dou et al., 2022). It acts on kidney inflammation, immunity, fibrosis, and energy metabolism and has a protective effect on the kidneys. Thus, the role of butyrate in kidney disease is an intriguing area of research.

Butyrate ameliorates kidney injury through the “gut–kidney axis”

A growing number of studies have suggested that kidney inflammation is related to bacterial load and endotoxins produced by gastrointestinal dysbiosis, which increases gut permeability and contributes to infection-related acute renal failure and chronic accelerated development of kidney disease (Li et al., 2019; Yang et al., 2019; Cai et al., 2020; Snelson et al., 2021). Several studies have observed significant differences in gut microbiota richness and populations between DKD patients and healthy controls (Jiang et al., 2016; Castillo-Rodriguez et al., 2018; Hu et al., 2020). This connection between the gut and kidney has been termed the “gut–kidney axis” (Leonel and Alvarez-Leite, 2012; Evenepoel et al., 2017).

A study by Terpstra ML (Terpstra et al., 2019) did not find significant differences in the number or capacity of the three most

Abbreviations: DKD, Diabetic kidney disease; SCFAs, Short-chain fatty acids; UACR, The ratio of urinary albumin to creatinine; LPS, Lipopolysaccharide; AMPK, AMP-activated protein kinase; β-arrs, β-arrestins; CKD, Chronic kidney disease; STZ, Streptozotocin; GPCRs, G-protein coupled receptors; CoA, Coenzyme A; NF-κB, Nuclear factor-kappa B; mRNA, Messenger RNA; Nrf2, Nuclear factor erythroid 2-related factor 2; mTOR, Mammalian target of rapamycin; miRNA, microRNAs; lncRNAs, Long non-coding RNAs; HDAC, Histone deacetylase; HG, High glucose.
abundant butyrate-producing bacteria (*F. prausnitzii*, *E. rectale*, and *Roseburia spp*) between end-stage renal disease patients and healthy kidney donors. However, butyrate has been shown to make a positive contribution to kidney disease in humans. A recent clinical study by Wang et al. (2019) indicated reduced SCFA levels in patients with chronic kidney disease (CKD), suggesting that butyrate supplementation may delay the progression of CKD. Of further interest is a recent study that showed quantitative reduction in SCFAs, especially butyrate, contributed to the progression of CKD (Wang et al., 2019). In a study by Cai et al. (2022), decreased serum butyrate levels were noted in the DKD group. Also, dysbiosis was evident in the gut microbiota of DKD patients, particularly associated with the lower abundance of SCFAs-producing bacteria belonging to the *Ruminococcaceae, Lachnospiraceae, and Butyricicoccus* groups. Li et al. (2022) also observed that the butyrate in serum was inversely connected with DKD. Given the substantial association between gut microbiota and butyrate, randomized controlled studies are necessary to examine whether alteration in the gut microbiota prevents DKD. Despite the controversy, the relationship between butyrate levels and renal injury has been proposed, indicating that butyrate may be a prospective target for the treatment of DKD. New mechanisms are being uncovered demanding the investigation of the role of endogenous butyrate on the “gut-kidney axis.”

**The molecular mechanism of butyrate-mediated renal protection**

Butyrate modulates the host’s biological responses mainly through the following mechanisms: (1) Butyrate directly inhibits HDAC (enzymes that remove acetyl groups from histone tails and regulate gene expression; Bose et al., 2014; Bridgeman et al., 2021). (2) Butyrate is involved in signalling through metabolite-sensing GPCRs. Three butyrate receptors have been identified, namely GPR41, GPR43, and GPR109A, out of the ten trophic receptor
GPR41 and GPR43

GPR41 and GPR43 have been identified as receptors for SCFAs, hence named free fatty acid receptors 3 and free fatty acid receptors 2, respectively (Brown et al., 2003). A previous study (Huang et al., 2020) by our research group evaluated the effects of three major SCFAs (acetate, propionate, and butyrate) on a high-fat diet and streptozotocin (STZ)-induced type 2 diabetes and DKD mouse models. The role and mechanism of butyrate in high glucose (HG)-induced mouse glomerular mesangial cells were explored to decipher new therapeutic strategies and molecular targets for DKD. We demonstrated that exogenous SCFAs, especially butyrate, partially ameliorated type 2 diabetes-induced kidney injury through GPR43-mediated inhibition of oxidative stress and nuclear factor kappa B (NF-κB) signalling. Our study suggested that butyrate may be a potential therapeutic agent for the prevention and treatment of DKD (Huang et al., 2020).

Both GPR41 and GPR43 activate the heterotrimeric G protein and subsequently unite with β-arrs (β-arrestins), which regulate the desensitization, internalization, intracellular signal transduction, and recirculation of GPCRs, and are responsible for the inflammation signalling pathway (Lee et al., 2013; Eichel et al., 2018). Huang et al. (2020) showed that HG induced the expression of βarr-2, but not βarr-1, and HG reduced the interaction between βarr-2 and 1-xB. However, this effect was reversed by butyrate via GPR43, suggesting that GPR43-β-arrestin-2 signalling could be a prospective target for DKD treatment. Nevertheless, numerous questions regarding the functionality of butyrate remain unanswered and disputed. Future research on GPR41 and GPR43 will require more effective and selective tools.

GPR109A

GPR109A was first identified as a niacin receptor activated by β-hydroxybutyrate and butyrate (Walters et al., 2009). As a ligand for GPR109A, butyrate reduces intestinal inflammation and promotes the integrity of the intestinal epithelial barrier, so activation of GPR109A is thought to have a protective effect (Macia et al., 2015; Feng et al., 2018). One study (Li et al., 2020) suggested that dietary fiber prevents DKD by regulating the intestinal flora, enriching SCFAs producing bacteria, and increasing SCFAs production, GPR43—/-- and GPR109A—/-- mice were sensitive to STZ-induced diabetes, indicating that GPR43 and GPR109A are indispensable for fiber and butyrate mediated protection against DKD. However, the mechanism of GPR109A in the pathogenesis and treatment of DKD needs further characterization.

HDAC inhibitor

Acetate, propionate, and butyrate have all been reported as HDAC inhibitors, with butyrate being the most widely studied. Also, amongst all SCFAs, butyrate was mentioned to have the most potent inhibitory effect on HDAC activity in vitro and in vivo. The maximum inhibition effectiveness of about 80% was observed for HDAC1/2, while that of propionate was about 60% (Corfe, 2012). Several reported effects of butyrate have been attributed to epigenetic effects that regulate the expression of genes in activated T cells, including NF-κB, myoblast antigens, p53, and nuclear factors, by inhibiting HDAC, increasing histone acetylation, and reducing histone densification (Wang and Friedman, 2000; Cruz-Bravo et al., 2014).

The mechanism of inhibition of HDAC activity by butyrate remains unclear. However, its benefits may be related to its anti-fibrosis, anti-inflammatory, and immunosuppressive effects in polycystic kidney disease (Vinolo et al., 2011; Manson et al., 2014; Khan et al., 2015). Oxidative stress contributes to the pathogenesis of DKD (Zhang et al., 2012; Keshari et al., 2015). Du et al. (2020a) found that sodium butyrate acts as an antioxidant and suppresses the HG-induced apoptosis in normal rat kidney tubular epithelial cells by inhibition of HDAC2. Sodium butyrate is also an activator of nuclear factor erythroid 2-related factor 2 (Nrf2, Yaku et al., 2012; Wu et al., 2018). Dong et al. (2017) first noted that Nrf2 was an important aspect of sodium butyrate’s mediated protection against DKD. Sodium butyrate may inhibit HDAC activity, facilitate the expression of the Nrf2 gene, which might enter the nucleus, and upregulate downstream targets-HO1 (heme oxygenase 1) and NQO1 (NAD (P) H dehydrogenase quinone 1). It also inhibits oxidative stress and inflammation in DKD. In contrast, in the absence of the Nrf2 gene, the role of sodium butyrate is eliminated. Although sodium butyrate seems to play a significant role via the activation of Nrf2, further studies are necessary before sodium butyrate can be suggested for use in humans.

The coagulation protease-activated protein C studies showed cytoprotective effects in vitro and in vivo disease models, including DKD (Madhusudhan et al., 2020). Activated protein C reduced glucose-induced hypomethylation and hyperacetylation of the p66hsc promoter in podocytes, sodium butyrate eliminated the protective effect of protease-activated protein C (Bock et al., 2013). Therefore, the role of butyrate as an HDAC modulator in the DKD is still controversial, and it is necessary to understand the mode of action of butyrate in intestinal physiology and lipid metabolism. The research will contribute to the consideration of butyrate as an HDAC inhibitor in preventing and treating DKD kidney injury.
Regulation of miRNAs

Recently, long non-coding RNAs (lncRNAs; Vinolo et al., 2011) and miRNAs (Du et al., 2020b) have been paid elaborate attention to decipher the molecular mechanisms of butyrate-mediated renal protection. miRNAs are small non-coding RNAs that regulate gene expression through the 3′ untranslated region of messenger RNAs (mRNAs). In DKD, extensive alterations in the expression of miRNAs such as miR-184 (Zanchi et al., 2017), miR-192 (Kato et al., 2013), and miR-21 (Kölling et al., 2017) was noted. Butyrate has been reported to influence miRNAs expression in oncogenic signalling pathways such as miR-92a, miR-22, miR-3,935, miR-574-3p, and miR-106B (Hu et al., 2015; Pant et al., 2017; Xiao et al., 2018). Du et al. (2020b) demonstrated that miR-7a-5p was prominently reduced in the HG-induced SV40-MES-13 cells and the kidneys of db/db mouse, while butyrate induced the upregulation of Mir-7a-5p. Later, the Mir-7a-5p inhibitors were administered to block the antifibrotic effects of butyrate.

Yang et al. (2021) also confirmed that sodium butyrate improved renal dysfunction in DKD model mice induced by db/db mice. Further RNA-seq results (Yang et al., 2021) showed that certain lncRNAs and miRNAs in the DKD+ sodium butyrate group had reverse changes compared with the DKD groups, and subsequent bioinformatics analysis also suggested that these changes might affect nephritis. These cumulative results indicated that sodium butyrate could protect DKD by altering the expression of lncRNA in mouse kidneys.

Autophagy

Autophagy is a highly conserved process and maintains cellular homeostasis (Liu et al., 2017). The expression of autophagy-related protein 7 in renal tubular epithelial cells was increased by SCFAs, suggesting that SCFAs regulate autophagy in acute kidney injury (Andrade-Oliveira et al., 2015). In colorectal and bladder cells, sodium butyrate also stimulated autophagy and inhibited tumor growth (Zhang et al., 2016; Luo et al., 2019; Wang et al., 2020). These results suggest a correlation between SCFAs and DKD via autophagy signaling.

AMPK is activated and downregulates the mTOR pathway under hunger or increased energy needs, which may induce autophagy to maintain homeostasis (Alers et al., 2012). AMPK phosphorylation was activated by butyrate in CKD rats, reducing renal injury (Gonzalez et al., 2019). Also, sodium butyrate causes autophagy-mediated cell death and reactivates the tumor suppressor gene DIRAS1 in the UOK146 renal cell carcinoma cell line (Verma et al., 2018). By increasing intestinal barrier function and activating the free fatty acid receptor 2-mediated PI3K/AKT/mTOR pathway, butyrate protects against DKD-induced muscle atrophy (Tang et al., 2022). Cai et al. (2022) first revealed that sodium butyrate boosted the phosphorylation of AMPK (Thr172), inhibited the phosphorylation of mTOR (Ser2448), and initiated autophagy in DKD rats. However, extensive research is needed to evaluate the mechanisms and interactions involved in gene knockout or overexpression in vitro and in vivo.

Histone butyrylation

We previously described that butyrate improves DKD by inhibiting HDAC (Khan and Jena, 2014; Dong et al., 2017; Du et al., 2020a). In the recent years, histone butyrylation (Chen et al., 2007), crotonylation (Tan et al., 2011), β-hydroxybutyrylation (Xie et al., 2016), and other novel histone post-translational modifications have been found. Pelletier N reported these mechanisms to cooperate or antagonize with histone acetylation and methylation, which plays a crucial role in gene expression regulation and cell fate decision (Pelletier et al., 2017). In 2007, Zhao Y’s team found that butyrate metabolite-butyryl-CoA, catalyzed by transcriptional coactivator P300 with acetyltransferase activity, can transfer the butyl group to the histone lysine side chain, and produce a novel modification-histone butyrylation (Chen et al., 2007). Yang et al. (2021) reported that butyrylation of histone H3K9 is negatively regulated by high-fat stress in mouse heart tissue. Also, Ishikawa-Kobayashi E and Gaikwad AB reported that the acetylation of H3K9 is involved in obesity and diabetic heart disease (Gaikwad et al., 2010; Ishikawa-Kobayashi et al., 2012). The β-hydroxybutyrylation of H3K9 up-regulated matrix metalloproteinase-2 and improved DKD (Luo et al., 2020). Nie et al. (2017) reported that the butyrylation of H3K18 in hepatocytes of high-fat induced obesity mice model significantly decreased, and the acetylation was up-regulated. The above studies thus suggest that the crosstalk between these modifications at the same lysine site may have synergistic or antagonistic effects on related gene expression. Since butyrate may induce butyrylation of histone, the role of this modification in the pathogenesis and prevention of DKD deserves further attention.

Application of butyrate in prevention and treatment of DKD

In a limited number of investigations conducted to date, butyrate or sodium butyrate has been used therapeutically in DKD in vivo and in vitro studies. Research conducted on the application of butyrate in DKD is summarized in Table 1.

Butyrate ameliorates DKD as HDAC inhibitor

In a study by Khan S (Khan and Jena, 2014), sodium butyrate reduced plasma glucose, creatinine, urea, histological alterations, and descent of the HDACs activity. It also curbed the expression of endothelial nitric oxide synthase, inducible nitric oxide synthase, alpha-smooth muscle actin, collagen I,
fibronectin, and transforming growth factor-β (TGF-β), and NF-κB in the kidneys of STZ-induced diabetic mice (Khan and Jena, 2014). However, Du Y’s study (Du et al., 2020a) showed that sodium butyrate as an HDAC2 inhibitor had no significance on the blood glucose levels of diabetic mice, though it significantly improved the ratio of urinary albumin to creatinine (UACR). Further, Dong et al. (2017) found that sodium butyrate did not alter blood glucose levels in STZ-induced diabetic C57BL/6 Nrf2 knockout and the WT mice, but significantly reduced UACR.

Surprisingly, Bock et al. (2013) reported that supplementing the drinking water with 8 g/l sodium butyrate eliminated the protective effect of activated protein C in diabetic mice. It further increased renal H3 acetylation, PAS-positive staining, nitrotyrosine accumulation, and urine albumin without affecting blood glucose levels or albuminuria in non-diabetic control donors.

### Table 1: Application of butyrate in vivo and in vitro model of DKD.

| Type                  | Model species                                      | Mode and dose                                      | Results                                                                                     | References        |
|-----------------------|-----------------------------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------|
| STZ-induced juvenile male SD rats | Sodium butyrate (500 mg/kg/day) by intraperitoneal injection | HDACs activity↑; BG↓; SCz↓; BUN↓; NOS↓; iNOS↓; a-SMA↓; collagen I↓; fibronectin↓; TGF-β↓; NF-κB↓; apoptosis↓; DNA damage↓ | Khan and Jena (2014) |
| STZ-induced C57BL/6 mice and Nrf2−/− mice | Sodium butyrate diet (5 g/kg/day) by oral gavage | BG (−); UACR↓; mesangial matrix↓; TGF-β↓; CTGF↓; PAI-1↓; HDAC activity↓; Nrf2↓ | Dong et al. (2017) |
| db/db mice           | Sodium butyrate (1 g/kg/day) by oral gavage         | BG (−); UACR↓; apoptosis↓ (BCL-2↓; Bax↓; caspase-3↓) | Du et al. (2020a) |
| db/db mice           | Sodium butyrate (1 g/kg/day) diet                   | BG (−); BW (−); mesangial matrix↓; UACR↓; collagen IV↓; PAI-1↓; a-SMA↓; CTGF↓; P311↓; miR-7a-5p↑; TGF-β↓ | Du et al. (2020b) |
| In vivo              | STZ-induced C57BL/6 mice                            | Sodium butyrate 100 mg/ (kg 48 h) by intraperitoneal injection | BW (−); FINS (−); blood lipid spectrum (−); RBG↓; FBG↓; IR↓; UACR↓; ScR↓; BUN↓; cystatin C↑; NF-κB↓; renal fibrosis↓ | Huang et al. (2020) |
| db/db mice           | Sodium butyrate (5 g/kg/day) by intraperitoneal injection | BW↓; BG↓; UACR↓; glomerular and tubular injuries↓ | Yang et al. (2021) |
| STZ-induced C57BL/6 mice | Sodium butyrate (50 mM) dissolved and administered to mice in drinking water | BG (−); UACR↓; podocytes/glomerulus↓; collagen-PSR↓; macrophage (CD68+)↓ | Li et al. (2020) |
| STZ-induced juvenile male SD rats | Sodium butyrate (8 g/3) dissolved and administered to mice in drinking water | H3 acetylation↑; nitrotyrosine accumulation↑; p66H±↑; albuminuria↑ | Beck et al. (2013) |
| db/db mice           | Sodium butyrate (1 g/kg/day) diet                   | Serum butyrate↑; ScR↑; and UACR↓; ZO-1↓; occludin↑ | Tang et al. (2022) |
| STZ-induced SD rats  | Sodium butyrate (300 mg/kg) by oral gavage         | Serum and fecal butyrate↑; BG↑; BUN↑; eGFR↑; fibronectin↑; collagen IV↑; LC3β↑; LC3BII↑↑; autophagosomes↑; mTOR↑; AMPK↑ | Cai et al. (2022) |
| Mouse kidney mesangial cells (SV40-MES 14 cells) | Sodium butyrate (5 mM) | lncRNA (+); mRNA (+) | Yang et al. (2021) |
| Mouse glomerular mesangial cells (SV40-MES 13) | Sodium butyrate (5 mM) | Oxidative stress↑ (ROS↑; MDA↑; SOD↓); inflammation↑ (ICAM-1↑; MCP-1↑; IL-1β↑) | Huang et al. (2017) |
| In vitro             | Mouse glomerular mesangial cells (SV40-MES 13)      | Sodium butyrate (5 mM) | ROS↑; MDA↑; MCP-1↑; IL-1β↑; NF-κB activation↑ | Huang et al. (2020) |
| Rat kidney tubular epithelial cells (NRK52E) | Sodium butyrate (0.1, 0.5, or 1.0 mM) | HDAC2↓; BCL-2↓; Bax↓; caspase-3↓; oxidative stress↓ (ROS↑; SOD↑; LDH↓) | Dong et al. (2017) |
| Mouse mesangial cells (SV40-MES 13) | Sodium butyrate (0.5 mM) | Collagen IV↓; PAI-1↓; a-SMA↓; CTGF↓; P311↓; miR-7a-5p↑; TGF-β1↓ | Du et al. (2020b) |
| Mouse kidney tubular epithelial cells and podocytes | Sodium butyrate (3.2 mM) | IL-6↓; fibronectin↓; TGF-β↓; TNF-α↓; MCP-1↓ | Li et al. (2020) |
animals. Chen et al. (2014) showed that in sodium butyrate-treated HBZY-1 cells (the rat mesangial cells), mRNA levels of monocyte chemotactic protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 significantly increased (1.7, 1.3 and 3.1 times). Apelin13, the most active member of the adipokine apelin group, inhibited sodium butyrate-induced inflammation and HDAC1 reduction in HBZY-1 cells by regulating histone acetylation (Chen et al., 2014). Therefore, a new mechanism was proposed to determine whether butyrate mediated inhibition of HDAC and contributed to the improvement of DKD. However, more studies are necessary to characterize and explain the controversial effects of endogenous butyrate.

Butyrate mitigates DKD acts as GPCRs agonist

In addition to protecting against DKD by inhibiting the HDAC pathway, butyrate also acts as an agonist of GPCRs to ameliorate DKD. DKD is a chronic low-grade inflammatory disease, and SCFAs have proven to positively affect inflammation and kidney injury (Huang et al., 2017; Xu et al., 2018). Previous studies by Huang et al. (2017) showed that butyrate and GPR43 agonists reversed the HG and LPS-induced mesangial cell proliferation, reduced reactive oxygen species and malondialdehyde generation, and controlled the inflammatory cytokine release. Ensuing research (Huang et al., 2020) evaluated the effects of butyrate in mice fed with a high-fat diet, with STZ-induced type 2 diabetes, DKD, and on HG-induced mouse glomerular mesangial cells. The results showed that exogenous butyrate improved blood glucose and insulin resistance and avoided UACR, mesangial matrix accumulation, and renal fibrosis in mice. Butyrate is responsible for the aforementioned effects via GPR43-mediated suppression of oxidative stress and NF-κB signalling.

Snelson et al. (2020) first studied the effects of GPR109A deficiency on DKD through analysis of GPR109A signalling deficiency on the development of DKD renal injury by GPR109A gene deletion. The findings of the long-term study (24 weeks) suggested that GPR109A deficiency does not play a vital role in the occurrence and development of DKD and gastrointestinal homeostasis. On the contrary, Li et al. (2020) explored the protective effects of dietary fiber on experimental DKD in STZ-induced diabetic mice or GPR43/GPR109A knockout mice. The diabetic mice fed on a high-fat diet had lower rates of albuminuria, glomerular hypertrophy, podocyte injury, and interstitial fibrosis compared with diabetic controls. Intake of fiber beneficially increased faecal and systemic SCFA concentrations and decreased the expression of inflammatory factors, chemokines, and fibrosis-promoting proteins in diabetic kidneys.

Since butyrate is recognized by the GPR109A, GPR41, and GPR43 receptors (Miyamoto et al., 2016), it has been argued that single-gene knockout models are insufficient to effectively illustrate the function of these receptors. This demands the use of double or triple knockout models (Tan et al., 2017). So far, the association between GPR41 and kidney injury has not been verified, and extensive studies are needed to investigate and further unravel the relationship between GPCRs and DKD.

Butyrate treats DKD by triggering autophagy

Recently, Cai et al. (2022) explored the protective effects and mechanism of sodium butyrate on STZ-induced DKD rats through activation of autophagy. They reported that oral sodium butyrate improved blood glucose, serum nitrogen levels, fibronectin, and collagen IV expression. They also confirmed that the beneficial effects of sodium butyrate on the said DKD phenotype were due to the activation of the AMPK/mTOR signalling pathway, which induces autophagy. Studies by Tang et al. (2022) also showed that sodium butyrate lowered serum creatinine, blood urea nitrogen, and UACR levels in DKD models replicated in db/db mice. They further evaluated the protective effects of butyrate against DKD-induced muscle atrophy. Butyrate provides a protective effect in db/db mice and HG/LPS-induced C2C12 myoblasts by suppressing autophagy and oxidative stress and activating the P38/PI3K/AKT/mTOR pathway. Since the relationship between autophagy and DKD is not entirely deciphered yet, butyrate's role in the regulation of autophagy and the prevention and treatment of DKD needs further evaluation.

Butyrate alleviates DKD by novel epigenetic mechanisms

We previously described the epigenetic control by HDAC inhibition mediated by butyrate that leads to amelioration of DKD, which recent studies have corroborated. Du et al. (2020b) found that butyrate alleviated renal dysfunction, serum creatinine and UACR levels, and mesangial matrix expansion in db/db mice by modulating the miR-7a-5p/P311/TGF-β1 pathway. However, no apparent differences in blood glucose levels and body weight were noted. As reviewed by Yang et al. (2021), sodium butyrate significantly improved body weight, urinary microalbumin, and urinary creatinine in diabetic mice by altering lncRNA expression, with no significant improvement in blood glucose levels.

Studies have found that butyrylation, similar to histone acetylation, can competitively inhibit gene transcription (Nie et al., 2017). Also, exogenous crotonate-mediated histone crotonylation inhibits the transcriptional activation of renal inflammatory genes and improves renal function in mice with acute AKI models (Ruiz-Andres et al., 2016). There is also evidence that histone β-hydroxybutyrylation is potentially beneficial for DKD (Luo et al., 2020). However, whether butyrate or sodium butyrate improves DKD renal injury through the histone butyrylation pathway has not been deciphered. Therefore, exploring the role of novel epigenetic mechanisms in DKD gene transcription regulation can provide great insights into the development of novel therapeutics against this disease.
Conclusion

All in all, endogenous butyrate or exogenous sodium butyrate supplementation improves body weight, glucose, and lipid metabolism, benefits a large population of type 2 diabetes, and protects against DKD, suggesting a new therapeutic reagent for DKD (Hong et al., 2016; Bridgeman et al., 2020). However, in vivo experiments have not clarified whether butyrate’s protective effect on DKD is independent or dependent on improving glycolipid metabolism, and the in vitro studies have reported that butyrate within a certain concentration range improves HG-induced renal intrinsic cells injury (Huang et al., 2017; Gu et al., 2019), but the harmful effects of butyrate have also been reported when the intervention concentration or time exceeds a certain level (Bock et al., 2013), furthermore, it is unclear whether the beneficial results observed in animal studies can be extrapolated to humans.

As shown in Figure 2, the molecular mechanism of butyrate improving DKD is extremely complex. As GPR41, GPR43, or GPR109A agonist, butyrate may exert anti-inflammatory effect through these receptors signalling pathways. At the same time, butyrate also acts as epigenetic regulators in response to the environment or therapeutic modulation by inhibiting HDAC,
up-regulation of miR-7a-5p, or induction of the histone butyrylation and autophagy processes. It is worth mentioning that butyrate-induced histone butyrylation, as a novel histone post-translational modification, has demonstrated its renal protective effects on diverse nephropathies, which provides a novel perspective for elucidating the pharmacological mechanisms of butyrate. Therefore, further basic experiments and well-designed clinical studies are necessary to explore the pharmacological effects and molecular mechanism of butyrate in DKD prevention and treatment.

Author contributions

WH contributed to the conception and design of the research. XC and TZ contributed to the design of the research. YoX and YH contributed to the acquisition and analysis of the data. YuX and WH contributed to the analysis, and interpretation of the data. All authors drafted the manuscript, critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the National Natural Science Foundation of China (Nos. 81800741 and 82170834), the Program of Sichuan Provincial Science and Technology Department (No. 2019Y0697 and 2018JY0059), and Office of Science Technology and Talent Work of Luzhou (No. 2020LZXNYDP02 and 2021LZXNYD-G01).

Acknowledgments

We would like to thank the Clinical Center Laboratory (Affiliated Hospital of Southwest Medical University) for technical assistance.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Alers, S., Löfller, A. S., Wesselhoeft, S., and Stork, B. (2012). Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, short cuts, and feedbacks. Mol. Cell. Biol. 32, 2–11. doi: 10.1128/mcb.06159-11

Andrade-Oliveira, V., Amano, M. T., Correa-Costa, M., Castoldi, A., Feltzardo, R. J., de Almeida, D. C., et al. (2015). Gut bacteria products prevent AKI induced by ischemia reperfusion. J. Am. Soc. Nephrol. 26, 1877–1886. doi: 10.1681/asn.2014030288

Bergman, E. N. (1990). Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol. Rev. 70, 567–590. doi: 10.1152/physrev.1990.70.2.567

Bock, F., Shahzad, K., Wang, H., Stoyanov, S., Wolfer, J., Dong, W., et al. (2013). Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc. Natl. Acad. Sci. U. S. A. 110, 648–653. doi: 10.1073/pnas.1218667110

Bose, P., Dai, Y., and Grant, S. (2014). Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol. Ther. 143, 323–336. doi: 10.1016/j.pharmthera.2014.04.004

Bridgeham, S., Ellison, G., Newsholme, P., and Mamotte, C. (2021). The HDAC inhibitor butyrate impairs β cell function and activates the disallowed gene hexokinase I. Int. J. Mol. Sci. 22. doi: 10.3390/ijms22213330

Bridgeham, S. C., Northrop, W., Melton, P. E., Ellison, G. C., Newsholme, P., and Mamotte, C. D. S. (2020). Butyrate generated by gut microbiota and its therapeutic role in metabolic syndrome. Pharmacol. Res. 160.105174. doi: 10.1016/j.phrs.2020.105174

Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Techeang, L., Daniels, D., et al. (2003). The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 13132–13139. doi: 10.1074/jbc.M211609200

Cai, K., Ma, Y., Cai, F., Huang, X., Xiao, L., Zhong, C., et al. (2022). Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury. Endocrinol. 76, 294–303. doi: 10.1007/s12200-022-03002-1

Cai, T. T., Ye, X. L., Li, R. R., Chen, H., Wang, Y. Y., Yong, H. J., et al. (2020). Resveratrol modulates the gut microbiota and inflammation to protect against diabetic nephropathy in mice. Front. Pharmacol. 11:249. doi: 10.3389/fphar.2020.00249

Castillo-Rodríguez, E., Fernández-Prado, R., Esteras, R., Perez-Gomez, M. V., Gracia-Igual, C., Fernandez-Fernandez, B., et al. (2018). Impact of altered intestinal microbiota on chronic kidney disease progression. Toxins 10.300. doi: 10.3390/toxins10070300

Chen, H., Li, J., Liu, J., Li, S. B., Peng, A., et al. (2014). Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J. Physiol. 592, 505–521. doi: 10.1113/jphysiol.2013.266411

Chen, Y., Sprung, R., Tang, Y., Ball, H., Sangras, B., Kim, S. C., et al. (2007). Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteom. 6, 812–819. doi: 10.1074/mcp.M700021-MCP200

Corrie, B. M. (2012). Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation. Mol. Biol. Cell 8, 1609–1612. doi: 10.1038/cmb25028d

Counillon, L., Bouret, Y., Marchig, I., and Pouyssegur, J. (2016). Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism. Biochim. Biophys. Acta 1863, 2465–2480. doi: 10.1016/j.bbamcr.2016.02.018

Cruz-Braço, R. K., Guevara-González, R. G., Ramos-Gómez, M., Oomah, B. D., Wiertzma, P., Campos-Vega, R., et al. (2014). The fermented non-digestible fraction of common bean (Phaseolus vulgaris L.) triggers cell cycle arrest and apoptosis in human colon adenocarcinoma cells. Genes Nutr. 9.339. doi: 10.1007/s12263-013-0359-1

Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., and Macfarlane, G. T. (1987). Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221–1227. doi: 10.1136/gut.28.10.1221

Dong, W., Jia, Y., Liu, X., Zhang, H., Li, T., Huang, W., et al. (2017). Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. J. Endocrinol. 232, 71–83. doi: 10.1530/joe-16-0322
Dou, X., Yan, D., Ma, Z., Gao, N., and Shan, A. (2022). Sodium butyrate alleviates LPS-induced kidney injury via inhibiting TLR2/4 to regulate RN22 expression. J. Food Biochem. 46:e14126. doi: 10.1111/jfb.14126.

Du, Y., Tang, G., and Yuan, W. (2020a). Suppression of HDAC2 by sodium butyrate alleviates cisplatin-induced renal failure in NRK-52E cells. Int. J. Mol. Med. 45, 210–222. doi: 10.3892/ijmm.2019.4397

Du, Y., Yang, Y. T., Tang, G., Jia, J. S., Zhu, N., and Yuan, W. J. (2020b). Butyrate alleviates diabetic kidney disease by mediating the miR-7a-5p/SPl1/TGF-β1 pathway. FEBS J. 334, 10462–10475. doi: 10.1111/febs.150341

Eschel, K., Julliet, D., Barsi-Rhyne, B., Latorraca, N. R., Masuerel, M., Sibarta, J. B., et al. (2018). Catalytic activation of β-arrestin by GPCRs. Nature 557, 381–386. doi: 10.1038/s41586-018-0079-1

Eslamal, D. A., Abou-Elghait, A. T., Ali, A. Y., Ali, M., and Bakr, M. H. (2020). Ultrastructural characterization of pancreatic β-cells is accompanied by modulatory effects of the HDAC4 inhibitor sodium butyrate on the PI3/AKT insulin signaling pathway in juvenile diabetic rats. Mol. Cell. Endocrinol. 503:110700. doi: 10.1016/j.mce.2019.110700

Evenepoel, P., Poesen, R., and Meijers, B. (2017). The gut–kidney axis. Pediatr. Nephrol. (Berlin, Germany). 32, 205–2014. doi: 10.1007/s00467-015-3527-x

Felizardo, R. J. F., de Almeida, D. C., Pereira, R. L., Watanabe, I. K. M., Destino, N. M., Candido, W. B., et al. (2019). Gut microbial metabolite butyrate protects against proteinuric kidney disease through epigenetic and PGR109A-mediated mechanisms. FEBS J. 334, 11994–11908. doi: 10.1111/febs.20190108

Feng, W., Wuu, Y., Chen, G., Fu, S., Li, B., Huang, B., et al. (2018). Sodium butyrate attenuates diarrhea in weaned piglets and promotes tight junction protein expression in colon in a GPR109A-dependent manner. Cell Physiol. Biochem. 47, 1617–1629. doi: 10.1007/s00592-019-01499-1

Gaiwatk, A. B., Sayed, S. G., Lichtenek, J., Tikoo, K., and Anders, H. J. (2010). Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am. J. Pathol. 176, 1079–1083. doi: 10.2353/ajpath.2010.090528

Gao, Z., Yin, J., Zhang, J., Ward, R. E., Martin, R. J., Lefevere, M., et al. (2009). Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1569–1577. doi: 10.2337/db08-0837

Gonzalez, A., Krig, R., Massey, H. D., Carl, D., Ghosh, S., Gehr, T. W. B., et al. (2016). Butyrate alleviates high-glucose-induced renal glomerular endothelial cells damage via inhibiting pyroptosis. Int. Immunopharmacol. 75:105832. doi: 10.1016/j.intimp.2019.105832

Guilloteaux, M., Martin, L., Eckhaut, V., Ducattel, R., Zabolotski, R., and Van, Immers, E. (2010). From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr. Res. Rev. 23, 366–384. doi: 10.1016/j.nutresrev.2011.02.003

Haenen, D., Zhang, J., Souza da Silva, C., Bosch, G., van der Meer, I. M., van Arkel, J., et al. (2013). A diet high in resistant starch modulates microbiota composition, SCFA concentrations, and gene expression in pig intestine. Nutr. J. 143, 274–283. doi: 10.1186/1475-2891-14-116972

Hong, J., Jia, Y., Pan, S., Jia, L., Li, H., Han, Z., et al. (2016). Butyrate alleviates high-fat diet-induced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice. Oncotarget 7, 56071–56082. doi: 10.18632/oncotarget.11267

Hu, S., Liu, L., Chang, E. B., Wang, J. Y., and Raufman, J. P. (2015). Butyrate protects against proteinuric kidney disease through short-chain fatty acid-mediated autophagy in colorectal cancer cells through LKB1/AMPK signaling. Mol. Cell. Endocrinol. 385, 1–12. doi: 10.1016/j.mce.2015.01.003

Kolling, M., Kaucsar, T., Schauerte, C., Hübner, A., Dettingl, A., Park, J. K., et al. (2017). Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice. Mol. Ther. 25, 165–180. doi: 10.1038/1001671

Kumar, A., Alrefai, W. A., Borthakur, A., and Dudake, P. K. (2015). Lactobacillus acidophilus counteracts enteropathic E. coli-induced inflammation by uptake in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G602–G607. doi: 10.1152/ajpgi.00816.2015

Lee, S. U., In, H. J., Kwon, M. S., Park, B. O., Jo, M., Kim, M. O., et al. (2013). F- Arresten 2 mediates G protein-coupled receptor 43 receptors 43 signals to nuclear factor-κB. Biol. Pharm. Bull. 36, 1754–1759. doi: 10.1248/bpb.b13-00312

Leonel, A. J., and Alvarez-Leite, J. L. I. (2012). Butyrate: implications for intestinal function. Curr. Opin. Clin. Nutr. Metab. Care 15, 47–47. doi: 10.1097/MONC.0b013e328353656a

Li, Y. J., Chen, X., Kwan, T. K., Loh, Y. W., Singer, J., Liu, Y., et al. (2020). Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated autophagy in type-2 diabetic rat: a comparative study with metformin. Chem. Biol. Interact. 254, 124–134. doi: 10.1016/j.cbi.2016.06.007

Luo, S., Li, Z., Mao, L., Chen, S., and Sun, S. (2019). Sodium butyrate induces autophagy in colorectal cancer cells through LKB1/AMPK signaling. J. Physiol. Biochem. 75, 53–63. doi: 10.1007/s40685-018-0651-z
continues from the previous page:

- Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 signaling and ameliorate diabetic nephropathy.

- Sodium butyrate supplementation ameliorates diabetic inflammation in db/db mice.

- Butyrate attenuates diabetes-induced aortic endothelial dysfunction via P300-dependent transcriptional activation of Nrf2.

- Downregulation of p53 by sustained JNK phosphorylation contributes to the progression of chronic kidney disease.

- Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the mTOR-385-Bmi1 axis in human bladder cancer cells.

- Sodium butyrate attenuates diabetes-induced aortic endothelial dysfunction via P380-mediated transcriptional activation of NrI.

- Butyrate’s expression is altered with metformin.

- Butyrate regulates liver mitochondrial function, efficiency, and dynamics in insulin-resistant obese mice.

- Butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53.

- Butyrate attenuates gentamicin-induced nephrotoxicity by its expression is altered with metformin.

- Butyrate and activin A coordinately restrict RhoA signaling and ameliorate diabetic nephropathy.

- Butyrate mediates the reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease.
kidney fibrosis in chronic kidney disease. *Nephrol. Dial. Transplant.* 34, 419–428. doi: 10.1093/ndt/gfy172

Yang, H., Zhang, Z., Peng, R., Zhang, L., Liu, H., Wang, X., et al. (2021). RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models. *Biosci. Rep.* 41:BSR20203005. doi: 10.1042/bsr20203005

Zanchi, C., Macconi, D., Trionfini, P., Tomasoni, S., Rottoli, D., Locatelli, M., et al. (2017). MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. *Diabetologia* 60, 1114–1125. doi: 10.1007/s00125-017-4248-9

Zhang, M. Z., Yao, B., Yang, S., Yang, H., Wang, S., Fan, X., et al. (2012). Intrarenal dopamine inhibits progression of diabetic nephropathy. *Diabetes* 61, 2575–2584. doi: 10.2337/db12-0046

Zhang, J., Yi, M., Zha, L., Chen, S., Li, Z., Li, C., et al. (2016). Sodium butyrate induces endoplasmic reticulum stress and autophagy in colorectal cells: implications for apoptosis. *PLoS One* 11:e0147218. doi: 10.1371/journal.pone.0147218

Zheng, Y., Zhang, Z., and Zhang, N. (2019). Protective effects of butyrate on renal ischemia-reperfusion injury in rats. *Urol. Int.* 102, 348–355. doi: 10.1159/000497476